Antiviral Information Management System (AIMS): A Prototype for Operational Innovation in Drug Development

被引:7
作者
Jadhav, Pravin R. [1 ]
Neal, Lauren [1 ]
Florian, Jeff [1 ]
Chen, Ying [1 ]
Naeger, Lisa [1 ]
Robertson, Sarah [1 ]
Soon, Guoxing [1 ]
Birnkrant, Debra [1 ]
机构
[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD 20093 USA
关键词
Drug development; knowledge management; hepatitis C virus (HCV); pharmacometrics; Antiviral Information Management System (AIMS); structural database; clinical trial simulations; learn-apply;
D O I
10.1177/0091270010376771
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article presents a prototype for an operational innovation in knowledge management (KM). These operational innovations are geared toward managing knowledge efficiently and accessing all available information by embracing advances in bioinformatics and allied fields. The specific components of the proposed KM system are (1) a database to archive hepatitis C virus (HCV) treatment data in a structured format and retrieve information in a query-capable manner and (2) an automated analysis tool to inform trial design elements for HCV drug development. The proposed framework is intended to benefit drug development by increasing efficiency of dose selection and improving the consistency of advice from US Food and Drug Administration (FDA). It is also hoped that the framework will encourage collaboration among FDA, industry, and academic scientists to guide the HCV drug development process using model-based quantitative analysis techniques.
引用
收藏
页码:50S / 55S
页数:6
相关论文
共 8 条
[1]   Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon [J].
Adinolfi, Luigi E. ;
Durante-Mangoni, Emanuele ;
Salzillo, Marta ;
Marrone, Aldo ;
Tripodi, Marie-Francoise ;
Restivo, Luciano ;
Merola, Antonietta ;
Zampino, Rosa ;
Ruggiero, Giuseppe .
INTERNAL AND EMERGENCY MEDICINE, 2009, 4 (06) :485-490
[2]  
[Anonymous], INN STAGN CHALL OPP
[3]  
CDC, HEP C INF HLTH PROF
[4]  
CODD EF, 1970, COMMUN ACM, V13, P377, DOI 10.1145/357980.358007
[5]  
*FDA, INN STAGN CRIT PATH
[6]  
GOBBURU JVS, PHARMACOMETRICS 2020
[7]   Deconstructing the Drug Development Process: The New Face of Innovation [J].
Kaitin, K. I. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :356-361
[8]   The state of innovation in drug development [J].
Kola, I. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :227-230